A new daily weight-loss pill could soon become a major breakthrough for people looking to maintain their weight loss after stopping treatments such as Mounjaro and Wegovy. Research published in Nature Medicine found that patients taking the oral medication Orforglipron every day for a year were able to maintain most of the weight they had already lost. The trial included hundreds of participants who had successfully reduced their weight before switching to either the pill or a placebo. At the end of the study, those taking Orforglipron managed to keep more than 70% of their previous weight loss off, while people taking the placebo regained significantly more weight. Researchers also reported that improvements in blood pressure, cholesterol and blood sugar levels were maintained in patients using the tablet. The medication works by mimicking natural hormones that help control appetite, reduce hunger and keep people feeling fuller for longer. Many experts believe oral medications like this could become increasingly popular with patients who prefer tablets as a simpler and more convenient treatment option. The findings also reinforce the growing understanding that obesity is a chronic condition that often requires ongoing medical support rather than a short-term solution. One of the biggest challenges patients face after stopping treatment is regaining weight, making long-term maintenance therapies an important area of research. Medical Specialists https://www.medical-specialists.co.uk/general-health/weight-loss.html are now offering a growing range of clinically approved weight-loss tablets designed to support weight management. Tablet-based treatments can provide an effective alternative for suitable patients looking for medically supervised support without the need for injections. As research into obesity treatments continues to evolve, experts believe new oral therapies could help make weight management more accessible, affordable and convenient for many patients in the future. You can read more about the study here: Nature Medicine article on Orforglipron